POSITRON CORP
10QSB, 2000-05-15
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Previous: TETRA TECHNOLOGIES INC, 10-Q, 2000-05-15
Next: TELIDENT INC /MN/, 10QSB, 2000-05-15




FORM  10-QSB                                                  MARCH  31,  2000
==============================================================================


                    U.S.  SECURITIES  AND  EXCHANGE  COMMISSION
                              Washington,  D.C.  20549



                                   FORM  10-QSB


   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE
                                   ACT OF 1934

                  FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2000


                         Commission file number: 0-24092



                                 [GRAPHIC  OMITED]

                                     POSITRON


                               A Texas Corporation
                               I.D. No. 76-0083622
            1304 Langham Creek Drive, Suite 300, Houston, Texas 77084
                                 (281) 492-7100


Indicate  by  check mark whether the issuer (1) filed all reports required to be
filed  by  Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
past  12  months (or for such shorter period that the registrant was required to
file such reports), and (2) has been subject to such filing requirements for the
past  90  days.

                    Yes     X          No
                       --------           -------


As  of  March  31, 2000, there were 57,474,554 shares of the Registrant's Common
Stock,  $.01  par  value  outstanding.

================================================================================
                                        1
<PAGE>
FORM  10-QSB                                                  MARCH  31,  2000
==============================================================================

                              POSITRON CORPORATION

                               TABLE  OF  CONTENTS
                 FORM  10-QSB  FOR  THE  QUARTER  ENDED  MARCH  31,  2000


<TABLE>
<CAPTION>
<S>                                                                       <C>

PART I - FINANCIAL INFORMATION                                            PAGE
                                                                          ----
Item 1.  Condensed Financial Statements

     Condensed Balance Sheets as of March 31, 2000 and December 31, 1999     3

     Condensed Statements of Operations for the three months ended
           March 31, 2000                                                    4

     Condensed Statements of Cash Flows for the three months ended
           March 31, 2000                                                    5

     Selected Notes to Condensed Financial Statements                        6

Item 2.  Management's Discussion and Analysis of Financial Condition and
                  Results of Operation                                       8

Signature Page                                                               9
</TABLE>

==============================================================================
                                        2
<PAGE>
FORM  10-QSB                                                  MARCH  31,  2000
==============================================================================

                              POSITRON CORPORATION
                            CONDENSED BALANCE SHEETS
                        (IN THOUSANDS, EXCEPT SHARE DATA)

<TABLE>
<CAPTION>



                                                                  March 31, 2000    December 31, 1999
ASSETS                                                             (Unaudited)           (Note)
- ------                                                          ----------------  -------------------
<S>                                                              <C>               <C>
Current assets:
  Cash and cash equivalents                                      $         5,760   $            7,180
  Accounts receivable, net                                                   854                  101
  Inventories                                                              1,001                  683
  Prepaid expenses                                                            75                  108
  Other current assets                                                       393                  150
                                                                ----------------  -------------------
          Total current assets                                             8,083                8,222

Plant and equipment, net                                                     111                  110
                                                                ----------------  -------------------

          Total assets                                           $         8,194   $            8,332
                                                                ================  ===================

LIABILITIES AND STOCKHOLDERS' DEFICIT
- ---------------------------------------------------------------
Current liabilities:
   Accounts payable, trade and accrued liabilities               $         3,850   $            3,766
   Unearned revenue                                                          109                  168
                                                                ----------------  -------------------
          Total current liabilities                                        3,959                3,934

Other liabilities                                                             39                   45
                                                                ----------------  -------------------
          Total liabilities                                                3,998                3,979

Stockholders' equity:
  Series A Preferred Stock:  $1.00 par value; 8% cumulative,
    Convertible, redeemable;  $1.00 par value; 5,450,000 shares
    Authorized; 980,942 shares issued and outstanding
   at March 31, 2000 and December 31, 1999.                                  981                  981
Common Stock:  $0.01 par value; 100,000,000 shares
    Authorized; 57,534,710 shares issued and 57,474,554 shares
    outstanding at March 31, 2000 and December 31, 1999.                     575                  575
Additional paid-in capital                                                53,917               53,917
Subscription receivable                                                      (30)                 (30)
Accumulated deficit                                                      (51,232)             (51,075)
Treasury Stock:  60,156 shares at cost                                       (15)                 (15)
                                                                ----------------  -------------------

           Total stockholders' equity                                      4,196                4,353
                                                                ----------------  -------------------

Total liabilities and stockholders' equity                       $         8,194   $            8,332
                                                                ================  ===================

</TABLE>

Note:  The consolidated balance sheet at December 31, 1999 has been derived from
the  audited  financial  statements at that date but does not include all of the
information  and  footnotes required by generally accepted accounting principles
for  complete  financial  statements.  See  accompanying  notes.

================================================================================
                                        3
<PAGE>
FORM  10-QSB                                                  MARCH  31,  2000
==============================================================================
                              POSITRON CORPORATION
                        CONDENSED STATEMENTS OF OPERATIONS
                        (IN THOUSANDS, EXCEPT SHARE DATA)
                                   (UNAUDITED)
<TABLE>
<CAPTION>
                                                                 Three Months Ended
                                                               ========================
                                                                March 31,    March 31,
                                                                  2000         1999
                                                               -----------  -----------
<S>                                                            <C>          <C>
Revenues:
    System sales                                               $      800   $       --
    Upgrades                                                           --           77
    Service and component                                             369          311
                                                               -----------  -----------
       Total Revenue:                                               1,169          388

Costs of sales and services:
    System sales                                                      398           --
    Upgrades                                                           --           28
    Service, warranty and component                                   115          114
                                                               -----------  -----------

       Total costs of revenues                                        513          142
                                                               -----------  -----------

        Gross profit                                                  656          246

Operating expenses:
    Research and development                                          255           69
    Selling and marketing                                             248           --
    General and administrative                                        395           91
                                                               -----------  -----------

        Total operating expenses                                      898          160
                                                               -----------  -----------
             Income (loss) from operations                           (242)          86

Interest income/(expense)                                              85          (52)
                                                               -----------  -----------

             Income (loss) from operations                           (242)          86

        Total other income (expense)                                   85          (52)
                                                               -----------  -----------

Net income (loss)                                              $     (157)  $       34
                                                               -----------  -----------

Basic and diluted earnings (loss) per common share             $     0.00   $     0.00
                                                               -----------  -----------
Weighted average number of basic Common shares outstanding         57,535       14,440
                                                               -----------  -----------
Weighted average number of diluted Common shares outstanding       57,535       16,207
                                                               -----------  -----------
     Common shares outstanding
</TABLE>


                             See accompanying notes
================================================================================
                                        4
<PAGE>
FORM  10-QSB                                                  MARCH  31,  2000
================================================================================

                              POSITRON CORPORATION
                       CONDENSED STATEMENTS OF CASH FLOWS
                                 (IN THOUSANDS)
                                   (UNAUDITED)
<TABLE>
<CAPTION>
                                                              Three Months Ended
                                                            ------------------------
                                                             March 31,    March 31,
                                                               2000         1999
                                                            -----------  -----------
<S>                                                         <C>          <C>
Cash flows from operating activities:
    Net income (loss)                                       $     (157)  $       34
    Adjustment to reconcile net income (loss) to net cash
            provided (used) in operating activities
         Depreciation                                               15           15
         Changes in operating assets and liabilities:
             Accounts receivable                                  (753)        (103)
              Inventory                                           (318)           6
              Prepaid expenses                                      33           --
              Other current assets                                (243)          --
              Accrued liabilities                                   84          (19)
              Unearned revenue                                     (59)          67
              Other liabilities                                     (6)          --
                                                            -----------  -----------
          Net cash used in operating activities                 (1,404)          --

Cash flows from investing activities:
      Capital expenditures                                         (16)          --
                                                            -----------  -----------
           Net cash used in investing activities                   (16)          --
                                                            -----------  -----------

Net decrease in cash and cash equivalents                   $   (1,420)  $       --

Cash and cash equivalents, beginning of period                   7,180            8
                                                            -----------  -----------

Cash and cash equivalents, end of period                    $    5,760   $        8
                                                            ===========  ===========
</TABLE>

                             See  accompanying  notes
================================================================================
                                        5
<PAGE>
FORM  10-QSB                                                  MARCH  31,  2000
==============================================================================

                              POSITRON CORPORATION
                   SELECTED  NOTES  TO  FINANCIAL  STATEMENTS

1.   BASIS  OF  PRESENTATION
     -----------------------

     The accompanying  unaudited interim financial statements have been prepared
     in accordance with generally accepted  accounting  principles and the rules
     of the U.S.  Securities  and  Exchange  Commission,  and  should be read in
     conjunction  with  the  audited  financial  statements  and  notes  thereto
     contained in the Company's  Annual Report of Form 10-KSB for the year ended
     December  31,  1999.  In  the  opinion  of  management,   all  adjustments,
     consisting  of  normal   recurring   adjustments,   necessary  for  a  fair
     presentation  of financial  position and the results of operations  for the
     interim  periods  presented  have been  reflected  herein.  The  results of
     operations  for  interim  periods  are not  necessarily  indicative  of the
     results to be expected for the full year. Notes to the financial statements
     which would substantially duplicate the disclosure contained in the audited
     financial  statements  for the most recent  fiscal year ended  December 31,
     1999, as reported in the Form 10-KSB, have been omitted.

2.   COMPREHENSIVE  INCOME
     ---------------------

     Effective  January 1, 1998,  the Company  adopted  Statement  of  Financial
     Accounting  Standard ("SFAS") No. 130,  "Reporting  Comprehensive  Income."
     Comprehensive  income includes such items as unrealized  gains or losses on
     certain  investment  securities and certain  foreign  currency  translation
     adjustments.  The  Company's  financial  statements  include  none  of  the
     additional  elements  that  affect   comprehensive   income.   Accordingly,
     comprehensive income and net income are identical.

3.   EARNINGS  PER  SHARE
     --------------------

     Basic earnings per common share are based on the weighted average number of
     common shares  outstanding in each year and after  preferred stock dividend
     requirements.  Diluted  earnings  per common share assume that any dilutive
     convertible preferred shares outstanding at the beginning of each year were
     converted at those dates, with related  interest,  preferred stock dividend
     requirements and outstanding  common shares adjusted  accordingly.  It also
     assumes that  outstanding  common shares were increased by shares  issuable
     upon  exercise  of those  stock  options  for which  market  price  exceeds
     exercise price,  less shares which could have been purchased by the Company
     with related  proceeds.  The  convertible  preferred  stock and outstanding
     stock options and warrants were not included in the  computation of diluted
     earnings  per  common  share for 2000 since it would  have  resulted  in an
     antidilutive effect.

     The following table sets forth the computation of diluted  weighted average
     shares outstanding:
<TABLE>
<CAPTION>
                                                                     Three Months Ended
                                                                   ======================
                                                                    March 31,   March 31,
(In Thousands)                                                        2000         1999
                                                                   -----------  ----------
<S>                                                                <C>          <C>
Numerator:
    Net income (loss)                                              $     (157)  $       34
                                                                   -----------  ----------
Denominator:
   Denominator for basic earnings per share-weighted
   average shares                                                      57,535       14,440
    Effect of dilutive securities:
        Convertible Series A preferred stock                               --        1,142
        Convertible Series B preferred stock                               --          625
                                                                   -----------  ----------
    Dilutive potential common shares                                       --        1,767
                                                                   -----------  ----------
    Denominator for diluted earnings per Share-adjusted weighted
            average shares and assumed conversions                     57,535       16,207
                                                                   ===========  ==========
</TABLE>


==============================================================================
                                        6
<PAGE>
FORM  10-QSB                                                  MARCH  31,  2000
==============================================================================

4.   INCOME  TAX
     -----------

     The  difference  between  the  Federal  statutory  income  tax rate and the
     Company's effective income tax rate is primarily  attributable to increases
     in valuation  allowances for deferred tax assets  relating to net operating
     losses.

5.   IMATRON  TRANSACTION
     --------------------

     In  May  1998,  the  Company   entered  into  an  agreement  (the  "Imatron
     Transaction") with Imatron Inc.  ("Imatron"),  pursuant to which in January
     1999, Imatron acquired a majority ownership of the Company.  In conjunction
     with the Imatron Transaction,  Imatron made working capital advances to the
     Company of  $600,000 to enable the Company to meet a portion of its current
     obligations.

     Upon  consummation  of the Imatron  Transaction  in January  1999,  Imatron
     acquired  a  majority  ownership  of the  outstanding  common  stock of the
     Company  on  a   fully-diluted   and   as-if-converted   basis   (excluding
     out-of-the-money warrants and options determined at the time of issuance of
     the shares of Imatron) and was issued nine million of the Company's  common
     stock in return for a nominal cash payment in the amount of $100.

     Imatron, in addition to providing limited working capital financing, agreed
     to support the  Company's  marketing  program  particularly  with regard to
     Imatron's affiliate, Imatron Japan, Inc. by agreeing to make all reasonable
     efforts to cause the  placement  of 10 POSICAM  systems over the next three
     years. During 1998 the Company shipped a POSICAM system to Imatron Japan as
     the first delivery under a three-year  distribution  agreement entered into
     during 1997. Imatron Japan, an affiliate of Imatron, is a major distributor
     for  Imatron's  Ultrafast  CT and for the  products  of certain  other high
     technology  companies.  Imatron  owns a 24  percent  minority  interest  in
     Imatron Japan.

     Imatron  has also agreed to help  facilitate  the  recapitalization  of the
     Company and to support its  re-entry  into the  medical  imaging  market by
     using its best efforts,  after the share issuance  closing date, to arrange
     for  additional  third-party  equity  financing  for  the  Company  over an
     eighteen-month period in an aggregate amount of at least $8,000,000.  There
     can be no  assurances,  however,  that  any such  sales  will  actually  be
     consummated or that Imatron will be able to successfully assist the Company
     in raising additional capital.

     In connection with the Imatron Transaction,  the Company, Imatron, and two,
     then current lenders, to the Company, Uro-Tech and ProFutures, entered into
     certain  agreements  whereby (a)  ProFutures  waived all past  defaults and
     extended  the  maturity  of the  ProFutures  Loan in  return  for a $50,000
     payment and the  issuance of warrants to purchase  1,150,000  shares of the
     Company's  common  stock  at  $0.25  per  share.  The  ProFutures  Loan was
     subsequently repaid in November 1998; (b) Imatron agreed to subordinate its
     loan to the ProFutures  Loan, (c) Uro-Tech  agreed to subordinate  its loan
     (with a current  balance of  approximately  $792,000 plus accrued  interest
     payable of approximately $272,000 at December 31, 1998) to Imatron's loan.

     In  August  of 1999,  Imatron  successfully  completed  raising a net $11.4
     million of equity capital for the Company.  This reduced  Imatron's current
     ownership  in  the  company  to  approximately  18%.  Consistent  with  the
     completion of the financing, the Company has repaid the Imatron bridge loan
     plus  interest  and paid the Uro-tech  loan plus  interest.  The  Company's
     President has resigned as Imatron's CFO and Imatron no longer has operating
     or voting control of the company.


=============================================================================
                                        7
<PAGE>
FORM  10-QSB                                                  MARCH  31,  2000
==============================================================================

     ITEM 2 - MANAGEMENT'S  DISCUSSION  AND ANALYSIS OF FINANCIAL  CONDITION AND
                             RESULTS OF OPERATIONS

We  are including the following cautionary statement in this Quarterly Report on
Form  10-QSB  to  make  applicable  and utilize the safe harbor provision of the
Private  Securities  Litigation Reform Act of 1995 regarding any forward-looking
statements  made  by,  or on behalf of, the Company.  Forward-looking statements
include  statements  concerning  plans,  objectives,  goals,  strategies, future
events or performance and underlying assumptions and other statements, which are
other  than statements of historical facts.  Certain statements contained herein
are  forward-looking  statements  and,  accordingly,  involve  risks  and
uncertainties, which could cause actual results or outcomes to differ materially
from  those  expressed  in  the  forward-looking  statements.

Our  expectations,  beliefs  and projections are expressed in good faith and are
believed  by  us  to have a reasonable basis, including without limitations, our
examination  of  historical  operating trends, data contained in our records and
other  data available from third parties, but there can be no assurance that our
expectations,  beliefs  or  projections  will  result,  or  be  achieved,  or be
accomplished.

COMPARISON  OF  THE  RESULTS  OF OPERATIONS FOR THE THREE MONTHS ENDED MARCH 31,
- --------------------------------------------------------------------------------
2000  AND  1999.
- ----------------

We  generated  a  loss  of  $157,000  for  the three months ended March 31, 2000
compared  to a profit of $34,000 for the three months ended March 31, 1999.  Our
current year loss was primarily the result of the hiring of additional personnel
and  increased  operating  expenses as we resumed full operation and production.

We  generated system revenue of $800,000 during the three months ended March 31,
2000  on  one  system sale versus no system revenue for the same period in 1999.
We  received  no  upgrade  revenue  for  the quarter versus $77,000 in 1999.  In
addition,  service  and component sales revenue increased $58,000 to $369,000 in
2000 from $311,000 during the same period in 1999 due to increased service work.
Service  revenue  increases  are attributable to normal fluctuations in service.

Our gross profit for the three months ended March 31, 2000 increased $410,000 to
$656,000  compared  to $246,000 for the three months in 1999.  This increase was
due primarily to the sale of a system and slightly better margins on the service
and  component  revenue.

Total  operating  expense  increased  $738,000  to $898,000 for the three months
ended March 31, 2000 from $160,000 for 1999. The increase results primarily from
significant  staff  additions and related operating expenditures in all areas as
we  went  back  into  full  operation  and  production.

Net  interest  income  was  $85,000 for the three months ended March 31, 2000 as
compared to net interest expense of $52,000 for the same  three  months  in 1999
due primarily  to  the  investment interest in first quarter 2000 on proceeds of
equity funding  from  August  of  1999.   During  the  first  quarter  of  1999,
interest was paid  on  the  Imatron  and  Uro-Tech  loans.

FINANCIAL  CONDITION
- --------------------

As  a  result  of the equity funding in August 1999, (see 5. Imatron Transaction
above), we began hiring personnel and incurring increasing operating expenses as
we resumed full operation and production.  Our return to full operation resulted
in  the  sale  of  our  first system in two years but also resulted in increased
overhead  and  operating  expenses.

Despite  the  first  quarter  system sale, we have previously been unable to
sell  our  POSICAMTM systems in sufficient quantities to be profitable and there
is  no  guarantee  that  we  will  reach a system sales level that will generate
profits  on  a  consistent  basis.  Consequently,  we have sustained substantial
accumulated  losses.  Due  to the sizeable selling prices of our systems and the
limited number of systems sold or placed in service each year, our revenues have
fluctuated  significantly  year-to-year.  We  have  an  accumulated  deficit  of
$51,232,000  at  March  31,  2000.


==============================================================================
                                        8
<PAGE>
FORM  10-QSB                                                  MARCH  31,  2000
==============================================================================


                                   SIGNATURES

Pursuant  to  the  requirements  of  the  Securities  Exchange  Act of 1934, the
Registrant  caused  this  report  to be signed on its behalf by the undersigned,
thereunto  duly  authorized.


                                        POSITRON  CORPORATION
                                        (Registrant)



Date:     May  12,  2000                /s/  Gary  H.  Brooks
                                       ----------------------
                                        Gary  H.  Brooks
                                        President
                                        (Duly  Authorized  Officer  and
                                        Principal  Accounting  Officer)


==============================================================================
                                        9
<PAGE>

<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1000

<S>                                     <C>
<PERIOD-TYPE>                           3-MOS
<FISCAL-YEAR-END>                       DEC-31-2000
<PERIOD-START>                          JAN-01-2000
<PERIOD-END>                            MAR-31-2000
<CASH>                                        5760
<SECURITIES>                                     0
<RECEIVABLES>                                 1796
<ALLOWANCES>                                   942
<INVENTORY>                                   1001
<CURRENT-ASSETS>                              8083
<PP&E>                                         439
<DEPRECIATION>                                 328
<TOTAL-ASSETS>                                8194
<CURRENT-LIABILITIES>                         3959
<BONDS>                                          0
                            0
                                    981
<COMMON>                                       575
<OTHER-SE>                                    2640
<TOTAL-LIABILITY-AND-EQUITY>                  8194
<SALES>                                        800
<TOTAL-REVENUES>                              1169
<CGS>                                          398
<TOTAL-COSTS>                                 1411
<OTHER-EXPENSES>                                 0
<LOSS-PROVISION>                                 0
<INTEREST-EXPENSE>                               0
<INCOME-PRETAX>                               (157)
<INCOME-TAX>                                     0
<INCOME-CONTINUING>                           (157)
<DISCONTINUED>                                   0
<EXTRAORDINARY>                                  0
<CHANGES>                                        0
<NET-INCOME>                                  (157)
<EPS-BASIC>                                    0
<EPS-DILUTED>                                    0


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission